Together, the findings of the FLAURA trial and preclinical studies may support the results of our study: that PD-L1 expression does not affect the efficacy of EGFR-TKIs or survival in untreated stage IV EGFR-mutated lung adenocarcinoma patients. The gene discussed is CD274; the disease is lung adenocarcinoma.